Given the strict eligibility criteria and the number of HIV positive patients followed in our HIV clinic, the minimal information included in a de-identified dataset may permit to identify a patient who took part in the study. Furthermore, the consent form the patients signed does not include permission to make detailed data openly available. For these reasons, the data underlying this study are available to interested and qualified researchers upon request. Data requests may be sent to the following body: Mrs Sakka, Bioethics Committee, Medical School, Aristotle University of Thessaloniki (Email:<bioethics@med.auth.gr>, Telephone number: +30 2310999338).

Introduction {#sec005}
============

Combination antiretroviral therapy(cART), albeit not curative, has improved substantially the morbidity and mortality of HIV disease through prolonged and sustained suppression of viral replication.\[[@pone.0194262.ref001]\] The establishment of HIV latency in a population of long lived memory CD4^+^ T cells is perceived as the major barrier for the eradication of HIV infection.\[[@pone.0194262.ref002]\] Several lines of evidence support the notion of persistent low level viral replication on cART at least in a subgroup of patients.\[[@pone.0194262.ref003]--[@pone.0194262.ref006]\] The importance of persistent HIV transcription(HIVpt) in patients on suppressive ART is unclear, but several studies suggest that biomarkers of HIVpt may be promising to assess residual viral replication.\[[@pone.0194262.ref007]\]

There is limited evidence derived from raltegravir intensification studies that residual viral replication as evidenced by increases in 2-long terminal repeat circles may affect to a lesser extent patients on non-nucleoside transcriptase inhibitors(NNRTIs) versus protease inhibitors(PIs).\[[@pone.0194262.ref003],[@pone.0194262.ref004]\] For drugs with steep dose-response curves such as PIs, small decreases in intracellular concentrations may diminish significantly the viral inhibition providing a plausible explanation for this observation.\[[@pone.0194262.ref008]\] Antiretroviral drugs may be substrates, inhibitors or inducers of ATP-binding cassette transporters(ABC transporters) which function as drug efflux pumps with possible implications for the intracellular concentrations of antiretrovirals.\[[@pone.0194262.ref009]\]

In our prospective study, we used a method which combines immunophenotyping with ultrasensitive-FISH to detect unspliced HIV-1 gag-pol in relevant cell populations in order to compare HIVpt in virologically suppressed patients on efavirenz(EFV) or atazanavir/ritonavir(ATV/r) and a backbone of emtricitabine-tenofovir(FTC-TDF).\[[@pone.0194262.ref007],[@pone.0194262.ref010],[@pone.0194262.ref011]\] We followed prospectively our patient cohort for one year and investigated the impact of HIVpt on virological outcomes and CD4+ T-cell recovery. Finally, we tested for differences in the mRNA expression of two widely studied ABC transporters (P-glycoprotein, P-gp/ABCB1 and multidrug resistance-associated protein-1, MRP1/ABCC1) in peripheral blood mononuclear cells(PBMCs) between patients with and without HIVpt by treatment regimen.

Patients and methods {#sec006}
====================

Study population and design {#sec007}
---------------------------

We conducted an observational prospective cohort study enrolling HIV-1 infected patients followed in the HIV clinic of the AHEPA University Hospital in Greece. The study was approved by the University Bioethics Committee and all patients provided written informed consent prior to study inclusion. Eligible patients were aviremic HIV-1 infected adults without hepatitis B or C co-infection on stable treatment for 12 months with either efavirenz or atazanavir/ritonavir and a backbone of emtricitabine---tenofovir disoproxil fumarate. Patients should be virologically suppressed (\<50 copies/ml) as determined with the standard of care method (Roche COBAS TaqMan HIV-test, v 2.0) at sampling and for the preceding 6 months. Age, risk factor for HIV diagnosis, country of origin, pretreatment viral load, nadir CD4 count, CD4 count within 3 months before enrollment (baseline CD4 count), CDC stage as well as time from HIV diagnosis to treatment initiation and time from treatment initiation to study enrollment were recorded. Patients were followed up according to guideline recommendations for clinical progression and virological suppression for a period of one year after sampling. The CD4 count one year after sampling was recorded to evaluate the impact of HIVpt on CD4 evolution. In a post hoc calculation, a sample of 22 patients per treatment group would have 80% power to detect a 40% difference in the prevalence of HIVpt between the two treatment groups (α = 0.05).

Samples {#sec008}
-------

We isolated PBMCs from 6ml of whole blood using Histopaque(Sigma Aldrich, USA), within 4 hours after collection. Viability and cell count were performed by using 7-AAD (Immunostep, Spain) staining. An average number of 3.96 million cells from each individual were stored in -20 °C for the total RNA extraction.

Simultaneous ultrasensitive subpopulation staining/hybridization in situ(SUSHI) {#sec009}
-------------------------------------------------------------------------------

In our study, we focused on HIVpt in the CD4^+^ as well as in the CD4^+^CD45RO^+^ memory T-cell subpopulation. Cell samples were incubated with appropriate volumes of CD4-PE and CD45RO-PE-Cy5 monoclonal antibodies (Biolegend, USA) and the expression of intracellular HIV-1 unspliced gag-pol HIV RNA was evaluated with SUSHI (ViroTect, IncellDx, USA) according to manufacturer's instructions. \[[@pone.0194262.ref012]\] Six HIV uninfected volunteers provided whole-blood samples and used as controls. We tested samples from 6 healthy volunteers with SUSHI and the percentage of positive cells ranged from 0.10% to 0.23%(median 0.16%). We adopted a cutoff of 0.3% which has been shown to correspond to 10--20 copies of HIV gag-pol unspliced RNA per cell and has been associated with significant lymphoproliferative responses to HIV-1 p24 in vitro. \[[@pone.0194262.ref010],[@pone.0194262.ref013]\] Measurements were conducted in a CyFlow Space flow cytometer(Sysmex-Partec).

Real-time qPCR analysis {#sec010}
-----------------------

Total RNA was extracted from PBMCs using the RNeasy Mini Kit for application in QIAcube automated system, according to the manufacturer's instructions(Qiagen). RNA concentration was determined with the NanoDrop 1000(Thermo Scientific); in order to evaluate the integrity and quality of the isolated RNAs, random samples were checked using an Agilent 2100 Bioanalyzer. Extracted RNA was stored in -80 °C. Total RNA (500 ng) was reverse-transcribed using RT^2^ First Strand Kit(Qiagen), according to the manufacturer's instructions.

We performed qPCR using Custom RT^2^ Profiler PCR Array(Qiagen) to compare the mRNA expression levels of P-gp(ABCB1) and MRP1(ABCC1) in patients with and without HIVpt on EFV-based versus ATV-based regimens. cDNA was combined with 2x RT^2^ SYBR Green MasterMix(Qiagen), and loaded onto an optically clear 96-well plate in duplicate where gene specific primers for target genes (ABCB1, NM_000927; ABCC1, NM_004996) and endogenous control gene (GSUB, NM_000181) were preloaded. At the same plate, genomic DNA contamination, efficiency of the reverse transcription reaction and efficiency of the polymerase chain reaction were tested by amplification of the genomic DNA control (HGDC, SA_00105), the reverse-transcription control (RTC, SA_00104) and positive PCR control (PPC, SA_00103) respectively. The cycling conditions were as follows: 95°C for 10 min, (95°C for 15 sec, 60°C for 1 min) × 40 cycles on the 7500 Fast Real-Time PCR System (Applied Biosystems).

Statistical analyses {#sec011}
--------------------

Continuous variables were summarized as mean and standard deviation(SD) for normally distributed data and as median and interquartile(IQR) otherwise. Discrete variables were expressed as percentages and 95% exact binomial confidence intervals(CI) were calculated. The independent samples t-test was used to compare normally distributed continuous variables and the Mann--Whitney for non-normally distributed variables. The chi-square test and the Fisher's exact test were used for discrete variables as appropriate. The association of various predictors with persistent HIV transcription status was evaluated with univariate logistic regression models. All statistical tests were two-sided. P-values less than 0.05 were considered statistically significant.

For gene expression analysis, raw Cq values of the expression of control and target genes were exported. The relative expression levels were calculated with the ΔΔCq method and fold-changes as 2^-ΔΔCq^. The expression levels were analyzed with Student's test and a sensitivity analysis was conducted with one-way ANOVA.

Statistical analyses were performed with IBM SPSS Statistics version 23 except for the sample size and the binomial confidence intervals calculations (R version 3.3.1 --stats(power.prop.test) and binom packages).\[[@pone.0194262.ref014],[@pone.0194262.ref015]\] Data visualization was executed with GraphPad Prism version 7.0(GraphPad Software).

Results {#sec012}
=======

During the period from October 2012 to July 2014, a total of 51 participants were enrolled in the study (30 on EFV and 21 on ATV). The two groups were similar in baseline cohort characteristics with the exception of time on HAART, which was longer in the ATV group (36 vs 27 months, p = 0.044) ([Table 1](#pone.0194262.t001){ref-type="table"}).

10.1371/journal.pone.0194262.t001

###### Cohort characteristics.

![](pone.0194262.t001){#pone.0194262.t001g}

                                                         Overall (N = 51)   EFV group (N = 30)   ATV group (N = 21)   p-value
  ------------------------------------------------------ ------------------ -------------------- -------------------- ---------
  Gender n, (%)                                                                                                       0.391
  Male                                                   46 (90.2%)         26 (86.7%)           20 (95.2%)           
  Female                                                 5 (9.8%)           4 (13.3%)            1 (4.8%)             
  Foreign origin n,(%)                                   3 (5.9%)           2 (6.7%)             1 (4.8%)             0.999
  Risk factor for HIV infection                                                                                       0.872
  MSM                                                    38 (74.5%)         23 (76.7%)           15 (71.4%)           
  Heterosexual contact                                   11 (21.6%)         6 (20%)              5 (23.8%)            
  IDU                                                    2 (3.9%)           1 (3.3%)             1 (4.8%)             
  Mean age (SD), years                                   42.2 (11.8)        40.1 (9.1)           45.2 (14.5)          0.123
  CDC stage at diagnosis n (%)                                                                                        0.575
  A                                                      33 (64.7%)         21 (70%)             12 (57.1%)           
  B                                                      15 (29.4%)         8 (26.7%)            7 (33.3%)            
  C                                                      3 (5.9%)           1 (3.3%)             2 (9.5%)             
  Months from HIV-1 diagnosis to ART(IQR)                20 (5--49)         26 (7--57)           18 (4--44)           0.117
  Months on ART (IQR)                                    31 (20--41)        27 (19--33)          36 (21--48)          0.044
  Nadir CD4^+^ cell count cells/mm^3^,median (IQR)       294 (191--331)     301(229--330)        223(153--349)        0.284
  Baseline CD4^+^ cell count cells/mm^3^, median (IQR)   613 (480--786)     606 (527--702)       687 (444--809)       0.950
  Pre ART viral load (copies/ml) log~10,~ SD             4.81 (0.69)        4.72 (0.74)          4.94 (0.61)          0.261

EFV: on treatment with efavirenz, tenofovir, emtricitabine, ATV: on treatment with atazanavir, tenofovir,emtricitabine, MSM: men having sex with men, IDU:intravenous drug users, SD: standard deviation, IQR:interquartile range, ART: antiretroviral treatment

Persistent unspliced HIV RNA transcription as captured by SUSHI was identified in the CD4^+^ cell populations in 23/51 patients (45.1%, 95% CI 31.1 to 59.7%): 13/30 patients in the EFV group(43.3%, 95% CI 25.5 to 62.6%) versus 10/21 in the ATV group(47.6%, 95% CI 25.7 to 70.2%). In the CD4^+^CD45RO^+^ cell population, persistent HIV transcription was present in 29/51 patients (56.9%, 95% CI 42.2 to 70.7%) with 14/30(46.7%, 95% CI 28.3 to 65.7%) in the EFV group versus 15/21 in the ATV group (71.4%, 95% CI 47.8 to 88.7%). The percentage of cells with persistent HIV transcription for each patient sample is depicted in [Fig 1](#pone.0194262.g001){ref-type="fig"}. In patients with HIVpt the percentages of HIV gag-pol^+^ cells were not different between the two treatment groups (p = 0.693 for CD4^+^ cells and p = 0.747 for CD4^+^CD45RO^+^ cells).

![Simultaneous ultrasensitive subpopulation staining/hybridization in situ (SUSHI) patient results by antiretroviral regimen in CD4^+^ and CD4^+^CD45RO^+^ T-cells.\
Two patients experienced a transient increase of their viral load in the follow-up period (black triangles). EFV: efavirenz, ATV/r: atazanavir/ritonavir.](pone.0194262.g001){#pone.0194262.g001}

In univariate logistic regression analysis, we observed a trend between the risk of HIVpt in the CD4^+^CD45RO^+^ cell population and ATV treatment (OR 2.86, 95% CI 0.87--9.37, p = 0.083) ([Table 2](#pone.0194262.t002){ref-type="table"}).

10.1371/journal.pone.0194262.t002

###### Predictors of HIV persistent transcription(HIVpt) in univariate logistic regression models.

![](pone.0194262.t002){#pone.0194262.t002g}

  --------------------------------------------------------------------------------------------------------------------------------------
  Predictor                                               HIVpt in CD4^+^ cells\   p-value   HIVpt in CD4^+^CD45RO^+^ cells\   p-value
                                                          OR (95% CI)                        OR (95% CI)                       
  ------------------------------------------------------- ------------------------ --------- --------------------------------- ---------
  ATV regimen (reference EFV regimen)                     1.19 (0.39--3.64)        0.762     2.86 (0.87--9.37)                 0.083

  Age per 10year increase                                 1.41 (0.85--2.31)        0.181     1.49 (0.89--2.50)                 0.133

  Nadir CD4 count per 100 cells/mm^3^ increase            0.96 (0.66--1.41)        0.835     1.02 (0.69--1.49)                 0.933

  CD4 count at sampling per 100 increase                  0.85 (0.66--1.09)        0.191     0.96 (0.77--1.21)                 0.742

  Pre ART viral load (copies/ml) per 1 log~10~ increase   1.25 (0.55--2.81)        0.596     1.19 (0.53--2.67)                 0.682
  --------------------------------------------------------------------------------------------------------------------------------------

ATV: on treatment with atazanavir, tenofovir, emtricitabine, EFV: on treatment with efavirenz, tenofovir, emtricitabine, ART: antiretroviral treatment, OR: odds ratio, CI: confidence interval

After study enrollment and sampling, one patient from the ATV group was lost to follow-up and one patient from the EFV group had a treatment switch due to renal toxicity to tenofovir. No patient presented clinical progression. Viral loads were below the limit of detection throughout the observation period in all patients, except for two patients in the EFV group who presented transient viral load elevations. Viral load was below the level of detection in subsequent evaluations. Of note, both patients were classified as negative with regard to HIVpt in the CD4+ T cell population and one was classified as positive in the CD4^+^CD45RO^+^ cell reservoir ([Fig 1](#pone.0194262.g001){ref-type="fig"}). A mean increase of 47 cells/ml (95 CI% 10 to 84 cells/mm^3^) was observed with no evidence of a difference between the two treatment groups(p = 0.240). HIVpt status in CD4^+^and CD4^+^CD45RO^+^ cells was not associated with the evolution of the CD4 cell count (p = 0.945 and p = 0.962, respectively-data available for 40 patients).

We did not observe differences in the levels of mRNA expression of P-gp and MRP1 between patients in the two treatment groups (P-gp: 1.14-fold difference, 95% CI 0.88 to 1.47 and MRP1: 1.05 95% CI 0.91 to 1.2). Furthermore, there was no evidence for differential expression of P-gp and MRP1 in patients with HIVpt versus those without HIVpt overall as well as in the two treatment subgroups.

Discussion {#sec013}
==========

In our prospective study, we compared the prevalence of HIVpt as evaluated by SUSHI among virologically suppressed patients on two popular first-line regimens at the time the study was designed (EFV-based versus an ATV-based). HIVpt status was confirmed in approximately half of the patients. There was no evidence of a difference in the prevalence of HIVpt between the EFV-group and the ATV-group in CD4^+^ cells. However, a trend for an association between an ATV regimen and the risk of HIVpt was observed in the CD4^+^CD45RO^+^ cell population. Furthermore, we did not observe an association between HIVpt status and CD4^+^ count evolution and the two patients with transient elevations of viral load that were observed did not map consistently into the HIVpt positive population. Finally, our data do not support a differential expression of the drug efflux transporters P-gp and MRP1 in PBMCs of patients with and without HIVpt.

The shift of the HIV research agenda towards strategies for the quantification and eradication of the viral reservoir has renewed interest in biomarkers beyond CD4^+^ cell counts and plasma viral load.\[[@pone.0194262.ref016]\] Cell-associated viral RNA(CA-RNA) in PBMCs has been linked to decreasing CD4+ T cell counts in untreated HIV patients,\[[@pone.0194262.ref017]\] and suggested as a predictor of treatment failure in patients on HAART.\[[@pone.0194262.ref018]\] Chronic immune activation and dysfunction seem to correlate with cell associated measures of viral persistence but further research is needed to disentangle the interactions between them.\[[@pone.0194262.ref019]--[@pone.0194262.ref022]\]

We used a conceptually different method which identifies individual cells with low levels of HIVpt, instead of relying on average values that may be skewed importantly by a minority of cells with high levels of CA-RNA. SUSHI has been used previously to evaluate the "active" reservoir of HIV which was linked to persistent HIV-1 specific immune response.\[[@pone.0194262.ref010],[@pone.0194262.ref012]\] The prevalence of HIVpt in virologically suppressed patients in our study is in line with previously published data.\[[@pone.0194262.ref010]\] In a recent study, similar levels of CA-RNA were found in PBMCs of PI versus NNRTI-treated aviremic patients,\[[@pone.0194262.ref020]\] and we replicated this finding with SUSHI in CD4 cells. However, different HIVpt profiles may be found in specific cell populations such as the memory CD4^+^CD45RO^+^ cells. Despite the fact that patients in the ATV group were on HAART for a longer period compared to the EFV group (36 vs 27 months, p = 0.044), the decay dynamics of cells with persistent HIV transcription suggest that such a difference should not impact the results meaningfully. \[[@pone.0194262.ref023]\]

Previous studies have suggested a role for CA-RNA as a predictive biomarker of virological failure(VF).\[[@pone.0194262.ref018]\] Our study was underpowered to evaluate such an outcome, but we were able to calculate the upper limit of the 95% confidence interval for the risk of virological failure in patients with HIVpt to 12.2%(0 VF cases out of 23 cases with HIVpt).\[[@pone.0194262.ref024]\] Furthermore, associations of HIVpt with pretreatment viral load and CD4 counts at sampling or before treatment initiation that have been previously reported were not replicated in our study.\[[@pone.0194262.ref018],[@pone.0194262.ref020]\] Finally, HIVpt status was not associated with decreased in CD4 cell recovery one year after sampling.

P-glycoprotein and MRP1 are among the most studied drug transporters that affect the disposition of antiretroviral drugs. We hypothesized that the interactions of antiretroviral drugs with these molecules may reduce the intracellular drug levels and be associated with HIVpt in PBMCs. Similarly, increases in CA-RNA levels in the absence of virological failure have been described in patients with suboptimal adherence to cART. \[[@pone.0194262.ref025]\] The variation in the mRNA expression of these transporters was not associated with virological failure or CD4 recovery in a small prospective study.\[[@pone.0194262.ref026]\] Our findings also do not support a correlation between drug transporters and HIVpt. Nevertheless, it should be noted that the interactions between antiretroviral drugs and the transporters are quite complex. \[[@pone.0194262.ref027]\]

Several limitations apply to our study. The identification of HIVpt with SUSHI may not reflect concomitant HIV protein production as transcripts may be defective. Nevertheless, such transcripts may still encode chimeric proteins with implications for HIV pathogenesis.\[[@pone.0194262.ref022]\] Except for the total CD4^+^ cells, we examined the CD4^+^CD45RO^+^ memory cell population which includes cells that contribute significantly to the latent HIV reservoir such as the central memory and effector memory cells.\[[@pone.0194262.ref028],[@pone.0194262.ref029]\] However, other relevant populations such as the memory stem cell population were not taken into consideration.\[[@pone.0194262.ref028]\] Similarly, our mRNA expression analysis was performed in total PBMCs and the transporter expression profile may be different in cell subpopulations. Further analyses of transporter protein expression with simultaneous determination of intracellular drug concentrations may provide further insights.

Large prospective studies with representative patient samples are required to validate the use of new biomarkers against clinical outcomes. Further study is required to evaluate whether persistence of HIV transcription may not affect to the same extent different cell populations across treatment regimens.
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